Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor.
Novel platelet glycoprotein IIb/IIIa receptor inhibitors have appeared as promising antithrombotic agents. However, their increased risk of bleeding complications, although known, is not well established. We report the case of a serious bleeding complication, a massive pulmonary hemorrhage, in a patient who was treated with one of these agents. Further studies defining guidelines and indications of treatment with platelet glycoprotein IIb/IIIa inhibitors are needed before their routine application to daily practice.
Sitges
M
M
Institut Clinic de Malalties Cardiovasculars, Barcelona, Spain.
Villa
F P
FP
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017023:Coronary Angiography; D003327:Coronary Disease / Q000628:therapy; D004562:Electrocardiography; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency; D013927:Thrombosis / Q000188:drug therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab